XNAS · Healthcare · Biotechnology
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Q1 2026 | -0.76 | -0.79 | -3.95% | $6.3M | ❌ Miss | +1.41% | +8.78% | +5.90% |
| 2026-01-28 | Q4 2025 | -0.89 | -0.82 | +7.87% | $13.6M | ✅ Beat | +1.57% | -7.39% | -10.63% |
| 2025-10-09 |
| Q3 2025 |
| -0.85 |
| -1.03 |
| -21.18% |
| $7.9M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-04-08 | Q1 2025 | -0.78 | -0.67 | +14.10% | $18.5M | ✅ Beat | +3.67% | +6.05% | +4.10% |
| 2025-01-28 | Q4 2024 | -0.71 | -0.75 | -5.63% | $13.3M | ❌ Miss | +0.46% | -4.96% | -23.31% |
| 2024-10-11 | Q3 2024 | -0.72 | -0.67 | +6.94% | $12.6M | ✅ Beat | +6.47% | +6.01% | +19.09% |
| 2024-07-11 | Q2 2024 | -0.64 | -0.71 | -10.94% | $12.1M | ❌ Miss | +8.13% | -3.99% | -3.72% |
| 2024-04-10 | Q1 2024 | -0.80 | -0.76 | +5.00% | $16.6M | ✅ Beat | +9.69% | -10.26% | -13.89% |
Showing last 8 quarters.